A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma

Lignende værker

• An open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myeloma
  af: Nishihori, Taiga, et al.
  Udgivet: (2015)
• Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial
  af: Jakubowiak, Andrzej J., et al.
  Udgivet: (2011)
• Cyclophosphamide–bortezomib–dexamethasone compared with bortezomib–dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma
  af: Figueiredo, A., et al.
  Udgivet: (2020)
• Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
  af: Yimer, Habte, et al.
  Udgivet: (2019)
• Pegylated liposomal doxorubicin for multiple myeloma
  af: Zeng, Zhiyong, et al.
  Udgivet: (2016)